Increases from baseline in ON-time with troublesome dyskinesia were not significantly greater for OPC 50 mg in comparison with PLC in all subgroup analyses (p ≥ 0.05), with the following exceptions: patients who received ≥5 L-DOPA intakes (p = 0.0095), patients with L-DOPA treatment duration ≥4 years (p = 0.0295), and patients with L-DOPA treatment duration ≥6 years (p = 0.0148)—all in the pairwise subgroups of patients who were in “later” phases (Supplementary Table 4). This evidence concerns the gene HSPG2 and Dyskinesia.